Letybo

Record type

Source-linked family profile

Recorded maker

Hugel / Croma-Pharma

Classification

Neuromodulator

Material identity

letibotulinumtoxinA · botulinum toxin type A

Snapshot date

14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Product names and regulatory context do not travel automatically between countries. Each row below is limited to its named source market.

• Letybo

  Hugel · Neuromodulator

1. Approved label

   1. Letybo 50 units — patient information leaflet

   Croma Deutschland GmbH via PatientenInfo-Service · Germany

   Open source ↗

   Supports: German product name, presentation, active-component wording, and leaflet revision context.

2. Manufacturer

   2. Letybo receives FDA approval

   Croma-Pharma · United States

   Open source ↗

   Supports: Manufacturer relationship and United States brand context.

3. Approved label

   3. Letybo 50 units — Summary of Product Characteristics

   electronic Medicines Compendium · United Kingdom

   Open source ↗

   Supports: The current UK product name, presentation, botulinum-toxin-type-A composition wording, and prescription context.

4. Approved label

   4. LETYBO — current United States drug label

   U.S. National Library of Medicine (DailyMed) · United States

   Open source ↗

   Supports: The United States LETYBO identity, Hugel packager context, and letibotulinumtoxinA-wlbg naming.

1. 1

   Identity

   Letybo is documented by current product-information sources in Germany, the United Kingdom, and the United States.

   Scope: The statement covers identity presence in the cited sources, not identical presentations or authorised uses.

   Evidence: Letybo 50 units — patient information leafletEvidence: Letybo 50 units — Summary of Product CharacteristicsEvidence: LETYBO — current United States drug label
2. 2

   Material / active name

   European sources use botulinum toxin type A wording; the US label uses letibotulinumtoxinA-wlbg.

   Scope: Names are transcribed by source market without an equivalence or conversion claim.

   Evidence: Letybo 50 units — patient information leafletEvidence: Letybo 50 units — Summary of Product CharacteristicsEvidence: LETYBO — current United States drug label

Use boundary

What this record does not establish

• Regulatory statusOnly within a source's named jurisdiction; family-profile review does not establish status elsewhere.
• Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
• Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
• Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.